These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7599677)

  • 1. Suramin.
    Eisenberger MA; Sinibaldi V; Reyno L
    Cancer Pract; 1995; 3(3):187-9. PubMed ID: 7599677
    [No Abstract]   [Full Text] [Related]  

  • 2. Other chemotherapy regimens including mitoxantrone and suramin.
    Siu LL; Moore MJ
    Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American studies on suramin therapy in hormone resistant prostate cancer.
    Rosen P; Belldegrun A
    Cancer Surv; 1995; 23():231-4. PubMed ID: 7621461
    [No Abstract]   [Full Text] [Related]  

  • 4. UK studies on suramin therapy in hormone resistant prostate cancer.
    Kehinde EO; Terry TR; Mistry N; Horsburgh T; Sandhu DP; Bell PR
    Cancer Surv; 1995; 23():217-29. PubMed ID: 7621460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
    Eisenberger MA; Nelson WG
    J Natl Cancer Inst; 1996 Jun; 88(12):779-81. PubMed ID: 8637038
    [No Abstract]   [Full Text] [Related]  

  • 6. Suramin and serum insulin-like growth factor levels in metastatic cancer patients.
    Miglietta L; Barreca A; Repetto L; Costantini M; Rosso R; Boccardo F
    Anticancer Res; 1993; 13(6B):2473-6. PubMed ID: 8135485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors.
    Scher HI; Heston WD
    Cancer Treat Res; 1992; 59():131-51. PubMed ID: 1347690
    [No Abstract]   [Full Text] [Related]  

  • 9. [Potentiation of cytotoxicity of electromagnetic shock waves by suramin, "in vitro" study].
    Rosell D; Robles JE; Aguera L; Abad JI; Rodríguez-Rubio FI; Zudaire JJ; Berian JM
    Actas Urol Esp; 1994 Jan; 18(1):29-33; discussion 34. PubMed ID: 8191943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials referral resource. Prostate cancer II.
    Cheson BD; Phillips PH; Kaplan RS
    Oncology (Williston Park); 1995 Jan; 9(1):50, 55. PubMed ID: 7718441
    [No Abstract]   [Full Text] [Related]  

  • 11. Suramin for prostate carcinoma.
    Harland SJ
    J Clin Oncol; 1992 Dec; 10(12):1985-6. PubMed ID: 1280675
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials referral resource. Clinical trials of suramin.
    Cheson BD; Phillips PH; Pluda JM; Christian M
    Oncology (Williston Park); 1995 Feb; 9(2):161, 163. PubMed ID: 8771098
    [No Abstract]   [Full Text] [Related]  

  • 13. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.
    Eisenberger MA; Fontana JA
    J Natl Cancer Inst; 1992 Jan; 84(1):3-5. PubMed ID: 1738171
    [No Abstract]   [Full Text] [Related]  

  • 14. Suramin and prostate cancer: where do we go from here?
    Clark JW; Chabner BA
    J Clin Oncol; 1995 Sep; 13(9):2155-7. PubMed ID: 7666073
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment strategies for hormone refractory prostate cancer.
    Redman BG; Pienta KJ
    Semin Urol; 1995 May; 13(2):164-9. PubMed ID: 7638474
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
    Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
    Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease.
    Van Oosterom AT; De Smedt EA; Denis LJ; de Bruijn EA; Mahler C
    Eur J Cancer; 1990 Apr; 26(4):422. PubMed ID: 2141506
    [No Abstract]   [Full Text] [Related]  

  • 19. New molecules and treatment modulation in advanced prostatic cancer.
    Mahler C; Verhelst J; Denis L
    Acta Urol Belg; 1996 May; 64(2):95-8. PubMed ID: 8701825
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
    Tisdale JF; Figg WD; Reed E; McCall NA; Alkins BR; Horne MK
    Am J Hematol; 1996 Feb; 51(2):152-7. PubMed ID: 8579057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.